Phase I study of EBV specific CTL generated from third party for treatment of EBV associated lymphoproliferative disorder after allogeneic stem cell transplantation

EBV specific CTL generated from third party for treatment of EBV associated lymphoproliferative disorder after allogeneic stem cell transplantation - EBV specific CTL for treatment of EBV associated LPD after stem cell transplant

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTa040190110

Enrollment

Registered

2020-01-22

Start date

2016-09-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EBV associated lymphoproliferative disorder after allogeneic stem cell transplantation

Interventions

Administration of EBV specific CTL induced and expanded from donor peripheral blood of third party

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Prior allogeneic hematopoietic stem cell transplantation 2. HLA-A0201, HLA-A0206, HLA-A2402 or HLA-1101 3. Rituximab resistant, difficulty in administering rituximab or CD20 negative EBV associated lymphoproliferative disorder 4. Written informed consent from patient or legal representative 5. Fulfill all of the following criteria: Performance status 0-3, GOT /GPT ==90% (room air)

Exclusion criteria

Exclusion criteria: 1. Severe or uncontrollable bacterial, fungal,and viral (except EBV) infection 2. Uncontrollable GVHD 3. Uncontrollable heart failure 4. Psychoses 5.History of allergic reaction to albumin

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events and graft-versus-host disease	—

Secondary

Measure	Time frame
Monitoring of EBV viral load and EBV specific CTL in peripheral blood Clinical course of EBV infection	—

Countries

Japan

Contacts

Public ContactKenji Hayashi

Nagoya University Hospital

ethics@med.nagoya-u.ac.jp+81-52-744-2479

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026